Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Joe Copia who wrote (5019)	6/11/1998 10:23:00 AM
From: Wayne Rumball	Read Replies (1) \| Respond to of 25711

Thursday June 11, 9:47 am Eastern Time Company Press Release SWISSRAY Awarded Contract From the Department of Veterans Affairs NEW YORK--(BUSINESS WIRE)--JUNE 11, 1998--SWISSRAY INTERNATIONAL, INC. (NASDAQ: SRMI - news) today announced that on May 22, 1998, one of its wholly owned subsidiaries, Swissray Medical Systems, was awarded a contract from the Department of Veterans Affairs estimated at $400,000 for the base year for its Diagnostic x-ray systems, the AddOn-Multi-System, with the VA reserving its option to extend the term of the contract up to March 31, 2001. The AddOn-Multi- System is the first ever FDA approved multifunctional direct digital radiography (ddR) system to be offered worldwide. It delivers plane x-ray examinations on the recumbent, seated and upright patient in a direct digital way. This system produces superior image quality, improved efficiency, productivity, and overall cost reduction. The AddOn-Multi-System is today's benchmark for direct digital radiography. Ueli Laupper, Vice President of Swissray International, Inc., stated, ''We are very pleased to have received the official award from the Department of Veterans Affairs. The VA healthcare system includes 171 medical centers and 362 outpatient, community and outreach clinics throughout the United States. With more than 80,000 medical center beds, the VA treats nearly a million patients a year, and registers nearly 23 million visits to VA's outpatient clinics for the same period, which represents an enormous customer potential. With the official contract award, we now can actively pursue sales to the VA hospitals, many of which have already expressed an interest in our AddOn-Multi- System.'' As an innovative developer and manufacturer of X-ray technology and systems, Swissray International, Inc. is a pioneer of direct digital radiography (ddR) technology, Swissray is, with its unique product line, the leader in direct digital X-ray systems. For more information about the Company and its AddOn-Multi-System(TM) visit the Swissray web site at swissray.com. This release contains certain forward-looking statements which involve known and unknown risks, uncertainties and other factors not under the Company's control which may cause actual results, performance achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. These factors include, but are not limited to, those detailed in the Company's periodic filings with the Securities and Exchange Commission. L.G. Zangani, LLC provides financial public relations services to the Company. As such L.G. Zangani, LLC and/or its officers, agents and employees, receives various forms of remuneration. Contact: UELI LAUPPER, Vice President International Sales & Marketing (212) 545-0095 or LEONARDO G. ZANGANI, Investor Relations (908) 788-9660 JEANNE FERRARI, Investor Relations (908) 788-9660

To: Joe Copia who wrote (5019)	6/11/1998 10:41:00 AM
From: Steven Messina,L.M.T.	Read Replies (1) \| Respond to of 25711

CMTR....I'm in at 3/8ths...looks like a nice daytrading stock thusfar. The Pfizer news didnt come out on the wire until late into the trading session yesterday. Most thought once this "news" was disseminated, there would be a gap up this morning. Well, one would think that obvious, however if you were a market maker in the stock, you'd sit on the BID as much as possible, holding her down in hope of causing some panic in those already up a good percentage...they bail at a small profit..mm's buy up on the cheap then let this baby fly short term. Wednesday June 10, 2:49 pm Eastern Time Company Press Release ChemTrak Signs Contract Research Pact With Pfizer Inc. SUNNYVALE, Calif.--(BUSINESS WIRE)--June 10, 1998--ChemTrak Inc. (Nasdaq:CMTR - news) Wednesday announced that it has signed an agreement with Pfizer Inc. of New York (NYSE:PFE - news) to develop a disposable, quantitative, fingerstick whole blood test for one of Pfizer's drugs in development using ChemTrak's patented AccuMeter technology. As part of the agreement, Pfizer will pay ChemTrak approximately $400,000 in quarterly installments over the next 18 months to develop the test. Pending successful clinical trials of the Pfizer drug, ChemTrak will remain the exclusive manufacturer of the AccuMeter Test. ChemTrak's proprietary AccuMeter platform is covered by 15 active patents and has four patents pending. Its technology is the foundation of three ChemTrak products; the CholesTrak Home Cholesterol Test, available at drug and mass merchandiser outlets, that allows consumers to monitor their progress while on a cholesterol lowering program; the AccuMeter H. pylori Test, used to detect the presence of antibodies to the bacterium associated with ulcers; and the ChemTrak AccuMeter Theophylline Test, recently cleared by the FDA, to monitor the concentration of the asthma drug Theophylline in blood. The technology is easily adaptable to monitor therapeutic drugs. ''We are extremely pleased Pfizer has chosen ChemTrak to develop a test for their drug,'' said Edward F. Covell, President and Chief Executive. ''We have been systematically streamlining and restructuring our R & D department to reflect our increased dedication to becoming a consumer-oriented marketing company. This has enabled us to focus our resources on the most innovative and productive R & D projects,'' he continued. ''Securing this new fully funded R & D project illustrates Pfizer's faith in the ease of use and dependability of our AccuMeter platform and it represents an excellent opportunity to become an OEM (Original Equipment Manufacturer) for Pfizer in addition to marketing our current product line,'' Covell said. ChemTrak's has a wide range of products for home use, which are available at all major chain drug and mass merchant outlets. ChemTrak's most recent addition to its over-the-counter line is the Parent's Alert Home Drug Test Service, a counselor supported home drug test service committed to helping parents prevent and eliminate drug abuse by their children. The CholesTrak Home Cholesterol Test, and the ColoCARE Home Test to Detect the Early Warning Signs of Colorectal Disease are both designed to help consumers take a more proactive role in their personal healthcare. Located in Sunnyvale, ChemTrak is a medical diagnostics company offering reliable and easy-to-use medical testing systems for in-home use and use in doctors' offices. ChemTrak medical tests are designed to screen and diagnose health conditions with accuracy comparable to laboratory tests. The statements in this release regarding products and revenues are forward looking and subject to risk and uncertainty, and future results could differ materially from past performance. For a detailed discussion of factors that may affect the company's operating results, interested parties should review the company's Securities and Exchange Commission reports, including the ChemTrak Form 10-Q for the quarter ended March 31, 1998, as well as the Annual Report on Form 10-K for the year ended Dec. 31, 1997, filed with the SEC. Contact: ChemTrak Inc., Sunnyvale, Calif. Donald V. Fluken, 408/773-8156 or Self & Associates Trudy M. Self, 818/880-5437 More Quotes and News: Chemtrak Inc (Nasdaq:CMTR - news) Pfizer Inc (NYSE:PFE - news)